ZA969945B - Long-lasting release nifedipine preparation - Google Patents

Long-lasting release nifedipine preparation

Info

Publication number
ZA969945B
ZA969945B ZA969945A ZA969945A ZA969945B ZA 969945 B ZA969945 B ZA 969945B ZA 969945 A ZA969945 A ZA 969945A ZA 969945 A ZA969945 A ZA 969945A ZA 969945 B ZA969945 B ZA 969945B
Authority
ZA
South Africa
Prior art keywords
hours
long
nifedipine
lasting release
dissolution test
Prior art date
Application number
ZA969945A
Other languages
English (en)
Inventor
Takaaki Nishioka
Kenji Kuratani
Haruo Kanasaki
Helmut Luchtenberg
Ulrich Tenter
Andreas Ohm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA969945B publication Critical patent/ZA969945B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
ZA969945A 1995-11-28 1996-11-27 Long-lasting release nifedipine preparation ZA969945B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33121795A JP3220373B2 (ja) 1995-11-28 1995-11-28 持続性ニフエジピン製剤

Publications (1)

Publication Number Publication Date
ZA969945B true ZA969945B (en) 1997-06-23

Family

ID=18241212

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA969945A ZA969945B (en) 1995-11-28 1996-11-27 Long-lasting release nifedipine preparation

Country Status (14)

Country Link
US (1) US5861173A (fr)
EP (1) EP0776660B1 (fr)
JP (1) JP3220373B2 (fr)
KR (1) KR970025607A (fr)
AT (1) ATE220898T1 (fr)
AU (1) AU709887B2 (fr)
CA (1) CA2191178C (fr)
DE (1) DE69622510T2 (fr)
ES (1) ES2180683T3 (fr)
IL (1) IL119684A (fr)
MX (1) MX9605646A (fr)
NZ (1) NZ299818A (fr)
SG (1) SG48492A1 (fr)
ZA (1) ZA969945B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN190974B (fr) * 1999-09-10 2003-09-06 Ranbaxy Lab Ltd
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
SE0004671D0 (sv) 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
KR100685945B1 (ko) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 액정표시장치 및 그 제조방법
US7883721B2 (en) 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
JP4817562B2 (ja) * 2001-09-26 2011-11-16 東和薬品株式会社 長時間持続型ニフエジピン有核錠
ATE376826T1 (de) * 2001-09-28 2007-11-15 Mcneil Ppc Inc Darreichungsformen zur modifizierten freisetzung
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2409552A1 (fr) * 2001-10-25 2003-04-25 Depomed, Inc. Forme posologique orale pouvant etre retenue dans l'estomac dont la liberation est limitee a la partie inferieure du tube digestif
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003227472A1 (en) * 2002-03-27 2003-10-08 Bayer Aktiengesellschaft Downsized core tablet containing nifedipine
EP1364644B1 (fr) * 2002-05-21 2008-09-17 Watson Laboratories, Inc. Composition pharmaceutique à libération prolongée
JP4563642B2 (ja) * 2002-05-31 2010-10-13 ワトソン ラボラトリーズ、インコーポレイテッド 医薬製剤
WO2004082665A1 (fr) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Composition à libération contrôlée
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
RU2391093C2 (ru) 2003-04-24 2010-06-10 Джаготек Аг Таблетка замедленного высвобождения с заданной геометрией ядра
US20040219210A1 (en) * 2003-05-01 2004-11-04 Jian-Hwa Guo Controlled release solid dosage nifedipine formulations
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
US7470293B2 (en) * 2004-10-29 2008-12-30 Idatech, Llc Feedstock delivery systems, fuel processing systems, and hydrogen generation assemblies including the same
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
DE102005031577A1 (de) 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
KR100774250B1 (ko) 2006-04-14 2007-11-07 넨시스(주) 1,4-디히드로피리딘 유도체 용출 제어형 과립제, 이의 정제및 이의 제조방법
MY149863A (en) 2006-08-03 2013-10-31 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
CN101677956A (zh) * 2007-06-11 2010-03-24 阿普尔顿纸张公司 包含有益剂的递送颗粒
JP5545952B2 (ja) 2007-08-31 2014-07-09 第一三共株式会社 徐放性製剤及びその製造方法
US20100316711A1 (en) * 2007-10-25 2010-12-16 Bayer Yakuhin ,Ltd. Nifedipine containing opress coated tablet and method of preparing same
US20090285889A1 (en) * 2008-05-14 2009-11-19 Capricom Pharma Inc. Modified release formulations of dihydropyridine compounds and methods of making same
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
AR081935A1 (es) 2010-06-16 2012-10-31 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada
WO2015186693A1 (fr) * 2014-06-02 2015-12-10 ニプロ株式会社 Comprimé pour impression laser et son procédé de fabrication
CA3011657A1 (fr) * 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations pour administration orale d'agents actifs
WO2017111178A1 (fr) 2015-12-24 2017-06-29 Takeda Pharmaceutical Company Limited Préparation solide
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3033919A1 (de) 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
NO883326L (no) * 1987-08-11 1989-02-13 Bayer Ag Dhp-retard-tilberedning.
DE3814532A1 (de) * 1988-04-29 1989-11-09 Bayer Ag Dhp-retard-zubereitung
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin

Also Published As

Publication number Publication date
ES2180683T3 (es) 2003-02-16
CA2191178A1 (fr) 1997-05-29
JPH09143073A (ja) 1997-06-03
NZ299818A (en) 1998-08-26
ATE220898T1 (de) 2002-08-15
AU7196096A (en) 1997-06-05
SG48492A1 (en) 1998-04-17
CA2191178C (fr) 2005-10-04
DE69622510D1 (de) 2002-08-29
KR970025607A (ko) 1997-06-24
AU709887B2 (en) 1999-09-09
IL119684A0 (en) 1997-02-18
US5861173A (en) 1999-01-19
IL119684A (en) 2000-09-28
EP0776660A2 (fr) 1997-06-04
DE69622510T2 (de) 2002-11-07
EP0776660B1 (fr) 2002-07-24
JP3220373B2 (ja) 2001-10-22
MX9605646A (es) 1997-06-28
EP0776660A3 (fr) 1998-01-21

Similar Documents

Publication Publication Date Title
ZA969945B (en) Long-lasting release nifedipine preparation
IL211075A (en) Multi-component preparation with irregular release
GB2196848B (en) Controlled release hydromorphone composition
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
CY2459B1 (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole.
CA2346001A1 (fr) Liberation regulee de compositions nanoparticulaires
DE69425932D1 (de) Schnellauflösliche pharmazeutische Dosierungsformen und Verfahren zu ihrer Herstellung
IL151150A0 (en) Multiparticulate drug form comprising at least two differently coated pellet forms
IE882921L (en) "new pharmaceutical preparation and process for its preparation"
MXPA02006780A (es) Formas de dosis de bencimidazol substituido novedosas y metodo para usar las mismas.
AU4121297A (en) Galenic form with extended release of milnacipran
HK1036417A1 (en) A non-stustained release, non-chewable pharmaceutical tablet composition
CA2334120A1 (fr) Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil
MXPA03011440A (es) Composicion de liberacion sostenida y proceso para producirla.
CA2342634A1 (fr) Composition pharmaceutique comprenant une entacapone ou nitecapone, de meme qu'un derive de cellulose reticule
DE59908764D1 (de) Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung
HK1043945A1 (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine.
IL103329A0 (en) Imidazole-5-carboxylic acid acylals,their preparation and pharmaceutical compositions containing them
CA2283255A1 (fr) Utilisation d'enantiomeres r d'anti-inflammatoires non steroidiens pour la prevention de la maladie d'alzheimer
CA2240281A1 (fr) Composition pharmaceutique a administrer par voie orale, a liberation modifiee, contenant du 5-asa et methode de traitement de maladies intestinales
ATE143010T1 (de) Pyridazin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
IT1252185B (it) Preparazioni farmaceutiche a liberazione programmata
DE69634080D1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel
GR3018795T3 (en) Emulsion-free emulsion polymers in sustained-release pharmaceutical compositions and their production
ATE2267T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepine, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen mit dopamin-rezeptor-blocker aktivitaet.